Table of contents


On 22 February 2018, orphan designation (EU/3/18/1987) was granted by the European Commission to Richardson Associates Regulatory Affairs Ltd, United Kingdom, for vocimagene amiretrorepvec (also known as Toca 511) for the treatment of glioma.

Key facts

Active substance
Vocimagene amiretrorepvec
Disease / condition
Treatment of glioma
Date of decision
Orphan decision number

Sponsor's contact details

Richardson Associates Regulatory Affairs Ltd
Tripps Farmhouse Lower End
Great Milton
Oxfordshire OX44 7NJ
United Kingdom
Tel. +44 (0)184 4279 821

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating